Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Excosine (also marketed as Excosine-S) is a brand of butylscopolamine bromide (hyoscine butylbromide) developed and marketed by Quimica Son's in Mexico. Butylscopolamine bromide is a peripherally acting antimuscarinic, anticholinergic agent that acts as a competitive antagonist at muscarinic acetylcholine receptors (primarily M3 and M2 subtypes) on smooth muscle cells of the gastrointestinal, biliary, and genitourinary tracts. By blocking acetylcholine-mediated signaling, it reduces smooth muscle contractions and spasms, providing rapid relief from abdominal cramps, colic, and related pain. Because of its quaternary ammonium structure, it does not readily cross the blood-brain barrier, minimizing central nervous system side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butylscopolamine bromide.